Equities

Medesis Pharma SA

Medesis Pharma SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.916
  • Today's Change0.00 / 0.00%
  • Shares traded31.88k
  • 1 Year change-56.38%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medesis Pharma SA is a France-based clinical development stage biopharmaceutical Company. The Company is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-2.79m
  • Incorporated2003
  • Employees10.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rapid Nutrition PLC1.82m-1.45m977.25k9.0041.79577.75--0.53790.00170.00170.00340.00011.843.903.05201,885.20-146.98---1,011.07--71.47---79.74--1.07--0.7674---1.50---1,090.33------
Theravet SA-100.00bn-100.00bn1.86m--------------------------------------------------------------
Biophytis SA0.00-17.03m3.09m26.00---------6.55-6.550.00-1.480.00-------100.31-97.52-1,481.81-487.25-----------12.25--------29.69--14.25--
Hybrigenics SA0.00-69.16k3.84m17.00--0.2742-----0.0003-0.00030.000.03610.00-------0.7067-35.48-0.877-48.94-------5,115.72----0.1032--100.00--78.83------
Medesis Pharma SA0.00-2.79m4.06m10.00---------0.6324-0.63240.00-0.5862------------------------1.14-23.17-----100.00---3.87------
IntegraGen SA12.49m-123.83k4.37m57.00--2.2553.670.3501-0.0179-0.01791.880.28871.249.093.09198,274.60-1.23-4.20-4.00-9.4364.7564.10-0.9913-3.671.23--0.418--16.2716.08-122.78------
Theranexus SA0.00-6.83m8.22m19.00--3.70-----1.09-1.090.000.28630.00----0.00-70.79-42.66-82.29-47.97-----------1,058.680.6212-------3.97---33.23--
Quantum Genomics SA10.06k-3.17m9.20m3.00--10.54--914.68-0.091-0.0910.00030.01250.0007--0.00163,353.33-23.14-60.77-95.19-102.24-14,205.07-3,548.91-31,520.38-3,374.13---146.530.8615---98.34--87.28------
Ikonisys SA538.56k-2.40m15.05m11.00--0.8235--27.94-0.2499-0.24990.0561.750.02461.146.2048,960.00-10.94---12.55--2.72---444.76--0.0818-36.790.1007--68.94---328.57------
Acticor Biotech SA0.00-18.65m15.47m24.00--32.93-----1.68-1.680.000.02980.00----0.00-145.59---297.22-------------9.320.9504-------25.94------
Data as of May 16 2024. Currency figures normalised to Medesis Pharma SA's reporting currency: Euro EUR

Institutional shareholders

0.14%Per cent of shares held by top holders
HolderShares% Held
Friedland Gestion SASas of 26 Jan 20246.00k0.14%
Data from 31 Jan 2024 - 31 Jan 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.